Drug Trial Radar · NCT05851092
Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors
Last checked: Nov 20, 2026Latest source record: Jul 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Planned (sponsor's estimate)
Start
May 26, 2023
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multi center, open label, dose increasing/dose expanding/efficacy expanding phase I clinical trial aimed at evaluating the safety, tolerance, PK characteristics, and anti-tumor efficacy characteristics of HRS-2189 single drug in patients with advanced malignant solid tumors. This study was divided into three stages: dose escalation, dose expansion, and efficacy expansion.
Conditions
- Advanced Malignant Tumor
Interventions
HRS-2189 TabletsDrug
HRS-2189 Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- AEs+SAEsTime frame: from the first drug administration to within 30 days for the last treatment dose
- Dose limited toxicity (DLT) of HRS-2189Time frame: up to 35 days
- Maximum tolerated dose(MTD)of HRS-2189Time frame: up to 35 days
- Recommended Phase II Dose (RP2D) of HRS-2189Time frame: up to 35 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.